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The Foot Orthoses versus Hip eXercises
(FOHX) trial for patellofemoral pain: a
protocol for a randomized clinical trial to
determine if foot mobility is associated
with better outcomes from foot orthoses
Mark Matthews1, Michael Skovdal Rathleff2,3,4, Andrew Claus1, Tom McPoil5, Robert Nee6, Kay Crossley7,
Jessica Kasza8, Sanjoy Paul9, Rebecca Mellor1 and Bill Vicenzino1*
Abstract
Background: Patellofemoral pain (PFP) is a prevalent, often recalcitrant and multifactorial knee pain condition. One
method to optimize treatment outcome is to tailor treatments to the patient’s presenting characteristics. Foot orthoses
and hip exercises are two such treatments for PFP with proven efficacy yet target different ends of the lower limb with
different proposed mechanisms of effect. These treatments have not been compared head-to-head, so there is a
dearth of evidence for which to use clinically. Only foot orthoses have been explored for identifying patient characteristics
that might predict a beneficial effect with either of these two treatments. Preliminary evidence suggests patients will do
well with foot orthoses if they have a midfoot width in weight bearing that is ≥ 11 mm more than in non-weight
bearing, but this has yet to be verified in a study that includes a comparator treatment and an adequate sample
size. This trial will determine if: (i) hip exercises are more efficacious than foot orthoses, and (ii) greater midfoot
width mobility will be associated with success with foot orthoses, when compared to hip exercises.
Methods: Two hundred and twenty participants, aged 18–40 years, with a clinical diagnosis of PFP will be randomly
allocated with a 1:1 ratio to receive foot orthoses or progressive resisted hip exercises, and stratified into two
subgroups based on their presenting midfoot width mobility (high mobility defined as ≥11 mm). The primary
outcome will be a 7-point Likert scale for global rating of change. All analyses will be conducted on an
intention-to-treat basis using regression models.
Discussion: This trial is designed to compare the efficacy of foot orthoses versus hip exercise, as well as to determine
if high midfoot width mobility is associated with better outcomes with foot orthoses when compared to hip exercises.
Results of this trial will assist clinicians in optimising the management of those with PFP by testing whether a simple
measure of midfoot width mobility can help to determine which patients are most likely to benefit from foot orthoses.
Trial registration: This trial is registered on the Australian New Zealand Clinical Trials Register (ACTRN12614000260628)
Keywords: Treatment effect modifier, Clinical prediction, Prognosis, Knee pain, Management
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Background
Patellofemoral pain (PFP) is a prevalent knee condition
throughout the lifespan [1–4], with a propensity to
become persistent [5, 6]. Patellofemoral pain classically
presents as anterior knee pain aggravated by activities
that load the patellofemoral joint, such as climbing or
descending stairs, running, squatting or sitting for pro-
longed periods [7]. Diagnosis is based on the clinical pres-
entation of PFP, in the absence of other pathologies that
might manifest as anterior knee pain [7].
Patellofemoral pain is also a multifactorial condition
with guidelines suggesting optimal treatment should
confer early pain relief and be targeted to the individual
[7, 8]. Physical and exercise interventions for PFP are
often targeted at the foot, knee and hip joints, or combi-
nations thereof, with combined interventions proving
superior [9]. Combined interventions for PFP often
involve both active (e.g., progressive resistance exercise)
and passive (e.g., orthoses, manual therapy, tape) therapies
applied to the knee as well as the foot, thigh and hip re-
gions. Selecting a tailored treatment plan for an individual
patient from this range of interventions will potentially
enhance treatment outcomes and minimise exposing
patients to non-essential treatments.
Clinical trials have shown that exercising the hip mus-
cles or using foot orthoses are efficacious in managing
PFP, [10–12] but no studies have compared which is
superior. Kinematic data suggests that the position and
movement of the femoral bone, which is largely governed
by hip joint movement under control of hip muscles, is
the main contributor to patellofemoral joint loads [13, 14].
Exercise of the hip muscles would then plausibly have
more effect on PFP through reduction of patellofemoral
joint load, when compared to interventions targeting the
foot (e.g., foot orthoses). We propose undertaking a
comparison between hip exercise and foot orthoses, as
it will address a common point of contention regarding
whether proximal or distal approaches to PFP are more
beneficial [15].
The recommendation to target treatments to the indi-
vidual [8] has not been researched. One method of
matching treatments to individual patients is to identify
patient characteristics that can predict success after a
specific treatment, known as treatment effect modifiers
[16]. There are currently no valid treatment effect modi-
fiers for treatment of PFP, but preliminary data suggest
that further investigation of midfoot width mobility is
warranted. Two studies have reported that greater mid-
foot width mobility [17] (defined as a change of 11 mm
or more moving from a weight bearing to non-weight
bearing posture) was present in greater proportions of
participants reporting improvement in their condition
when treated with foot orthoses [11, 18]. These prelim-
inary studies are limited in terms of the methods
required to prove treatment effect modification [19].
Such limitations include failure to compare the specific
intervention of interest against another relevant treat-
ment and testing too many potential predictor variables
for the sample size studied.
We will undertake a randomized clinical trial that will
investigate the role of midfoot width mobility as a treat-
ment effect modifier for treatment of PFP with foot
orthoses. It will also evaluate the clinical efficacy of foot
orthoses against progressive resisted hip exercises. The
prospective trial will stratify participants based on their
midfoot width mobility and randomly allocate them to
be treated with foot orthoses or hip exercises.
The objective of this trial is to determine if those indi-
viduals with PFP and greater midfoot width mobility will
report better outcomes from foot orthoses when com-
pared to hip exercises. The trial will also conduct a dir-
ect comparison between foot orthoses and hip exercises
in the treatment of PFP.
Hypotheses:
(i) High midfoot width mobility is a treatment effect
modifier for foot orthoses compared to progressive
resisted hip exercises at 12 weeks. This means that
beneficial effects of foot orthoses compared to hip
exercises will be greater for patients with PFP who
have high midfoot width mobility than in those who
have low midfoot width mobility.
(ii)Hip exercises will be associated with better
outcomes after 12 weeks, when compared to
treatment with foot orthoses
Method
This study protocol follows the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) guidelines [20]. The study report will follow
the CONSORT guidelines for randomized trials [21]
with the extension for non-pharmacological treatments
and TIDieR for intervention description [22, 23].
Trial design
A two-arm prospective randomised superiority clinical
trial in a multicentre setting with stratification on midfoot
width mobility will evaluate if midfoot width mobility is a
treatment effect modifier for foot orthoses compared to
progressive resisted hip exercises. An independent off-site
body will generate a randomisation schedule for all partic-
ipants for both trial sites. Participants will be allocated
into either foot orthoses or progressive resisted hip exer-
cises in a 1: 1 ratio using permuted block randomisation
stratified by site and by the mid foot mobility measure.
The primary end point will be 12 weeks.
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Study setting
The trial will be conducted in Brisbane, Australia and
Aalborg, Denmark. To reflect the common treatment
settings in these countries, participants in Brisbane will
attend private physiotherapy practices in the community
while those is Aalborg will attend physiotherapy sessions
in a hospital musculoskeletal outpatient department [24].
Eligibility criteria
Volunteers will range from 18 – 40 years of age, report a
history of anterior, retro or peri-patellar knee pain of
non-traumatic origin that has persisted for more than
six weeks. Self-reported worst pain over the previous week
will be required to be greater than 3/10 on a numerical
pain scale (0 = no pain, 10 = worst pain imaginable) with
symptoms provoked by at least two or more of the fol-
lowing activities: squatting, running, prolonged sitting,
stair ascending or descending. On physical examination,
pain should be provoked by clinical palpation of the patel-
lar borders, stepping down from a 25 cm step, during a
double-leg squat and present on clinical compression of
the patella into the trochlear groove. Eligible participants
will be required to have basic comprehension of written
and spoken English (Brisbane, Australia) or Danish
(Aalborg, Denmark) because of the descriptive nature
of pain and behavioral outcome measures applied in
this study.
Volunteers will be excluded if they have any of the fol-
lowing: concomitant injuries or pathologies affecting
other knee structures (e.g. ligament, meniscal, tendon,
iliotibial band, pes anserinus), a history of knee or other
significant lower limb surgery, patellofemoral dislocation
or subluxation, Osgood-Schlatter’s disease, Siding-
Larsen-Johanssen syndrome, a positive patellar appre-
hension test or evidence of knee joint effusion. Volun-
teers will be excluded if they present with any foot
condition that may preclude the use of foot orthoses,
pain in and/or referred from the hip, pelvis or lumbar
spine, current use of anti-inflammatory or corticosteroid
medication including injections, or any previous treat-
ment for PFP or other conditions that included hip exer-
cises or foot orthoses.
Stratification criterion
An investigator at each trial site, different to the investi-
gator responsible for enrolment, baseline and follow up
outcome measures and blind to those outcome mea-
sures, will measure each participant’s midfoot width
prior to treatment allocation. Midfoot width mobility is
calculated as the difference in midfoot width between
weight bearing and non-weight bearing postures and
shown to be reliable [17]. The investigators taking the
midfoot width mobility measurement will be trained to
ensure they can reliably measure midfoot mobility. To
test for midfoot width mobility as a treatment effect
modifier for foot orthoses, we determined prior to the
study that the stratification cutoff for midfoot width
mobility will be 11 mm [11, 18]. Those who present with
≥11 mm midfoot width mobility will be defined as being
‘high mobility’ and those with <11 mm as ‘low mobility’.
Interventions
Eligible participants will be randomly assigned to one of
two interventions; (a) foot orthoses intervention or (b) a
progressive resisted hip exercise intervention. Registered/
licenced physiotherapists who regularly treat musculo-
skeletal conditions will deliver both interventions.
Treating physiotherapists at both sites will be trained
by the same investigators (BV, MM & MSR) in the
intervention protocols for both foot orthoses fitting and
hip exercises prior to trial commencement to ensure
consistent implementation of the interventions. Al-
though the treatments are standard physiotherapy in-
terventions, to ensure fidelity of treatment application
all clinicians will be provided with extensive documen-
tation including images of treatments, have an option to
attend a refresher workshop, and access to a senior inves-
tigator for any queries or issues that arise during the trial.
Treating physiotherapists will be blind to the participant’s
midfoot width mobility measurements and baseline and
follow-up outcome measurements. At the start of the
study all participants will receive education to facilitate a
basic understanding of their PFP condition and advice on
physical activity. Participants will be encouraged to re-
main physically active provided that their chosen activ-
ities do not provoke pain that persists after ceasing their
activities, and there is no general deterioration of symp-
toms during or after the cessation of activity.
Foot orthoses
Prescription of foot orthoses will follow the protocol uti-
lised in a previous randomised control trial [10]. Physio-
therapists will be provided with a range of commercially
available prefabricated foot orthoses (Vasyli Inter-
national, Labrador, Australia) (Fig. 1). The orthoses are
manufactured and designed from ethylene-vinyl acetate
with an inbuilt arch support and a manufacturer speci-
fied 6° varus wedge. The orthoses are constructed in 3
different levels of hardness [high (Shore A 75°), medium
(Shore A 60°) or low (Shore A 52°)]. Prior to fitting the
orthoses, the participant will perform a nominated ag-
gravating task (e.g., step-ups). Physiotherapists will then
follow a standardised fitting procedure (Fig. 2). The
physiotherapist has the scope within the fitting procedure
to review the size, length, and hardness of the orthoses,
that prioritises comfort as this is a key determinant of
participant compliance [25]. To maximise comfort of
the orthoses, physiotherapists can make modifications
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including heat moulding and/or trialing various medial
wedges to the rear foot (2° or 4° inclination) and/or forefoot
(4° or 6° inclination) and/or heel raise (4, 6 or 8 mm in
height). Once the participant is satisfied with the comfort
of the orthoses, the participant will perform the previously
nominated aggravating task. An improved performance
will be determined by the participant reporting a reduc-
tion in pain score or improved performance (e.g. more
repetitions of an aggravating activity) before the onset of
their pain.
The prescribing physiotherapist will have 3 attempts
to modify the foot orthoses to primarily be comfortable
and then improve performance of the participant
selected task. In the unlikely event that the foot orthosis
cannot be modified sufficiently to the participant’s satis-
faction by the third session, then the participant will be
Fig. 1 Orthoses types. (From front) Full length, three-quarter length, easy fit & contoured sandal
Fig. 2 Flowchart of orthoses fitting procedure
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deemed unsuitable for foot orthoses. That is, no partici-
pant will be asked to wear orthoses that they perceive is
uncomfortable. Previous trials of the same population
using the same fitting procedure reported that no partici-
pants were unsuitable for this intervention [10, 11].
To encourage wearing of the orthoses, participants will
be prescribed up to four pairs to fit a wide range of foot-
wear as well as contoured (in the form of the orthoses)
sandals for everyday use. Participants will be encouraged
to wear the orthosis or contoured sandal whenever weight
bearing. The sandal and orthoses have been shown to
similarly increase arch height in healthy participants [26].
Participants receiving orthoses will also be asked to
perform a home foot and ankle exercise program twice
per day (Fig. 3). The program will include (i) stretches
for the triceps surae/tendo-Achilles complex (3 × 30 sec
weight-bearing), and (ii) anti-pronation postural foot
exercises. The anti-pronation foot exercises aim to
improve the participant’s awareness from a relaxed pro-
nated posture to a more supinated posture. Therapists
will initiate training of the foot exercises with partici-
pants seated with the knees flexed and bare feet on the
ground. Training consists of verbal and manual facilita-
tion of participants to supinate the rear foot (manual
facilitation: therapist upward pressure under the
navicular as well as palpating the talocrural joint space
for medio-lateral symmetry), while maintaining the first
metatarsal head firmly on the floor and the toes relaxed.
This foot posture will be held for 5 × 10 s. The exercises
will be performed on each foot separately. Participants will
attend a total of six sessions over six weeks.
Hip exercises
The progressive resisted hip exercise protocol is modi-
fied from a protocol successfully used to improve out-
comes at 12 months in women with PFP [27]. Exercise
therapy focused on hip muscle groups, in particular hip
abductor, external rotator, and extensor muscle groups,
as well as a knee strengthening and stretching program
targeting quadriceps, hamstrings and triceps surae
muscle groups [27]. Results from intervention studies
[12, 27–31] support that exercises targeting the postero-
lateral hip musculature can improve long-term function
and reduce PFP when compared to no exercises or knee
exercises alone [32].
Participants in the progressive resisted hip exercise
group will attend three sessions per week for four weeks
(12 sessions) [27] to perform exercises focused on the
hip abductor (Figs. 4 and 5), extensor (Fig. 6) and exter-
nal rotator (Fig. 7) muscles groups. The exercises will be
performed alternately on both sides and are described in
Table 1 [33]. Elastic bands will provide resistance for the
exercises and will be standardized to allow the partici-
pant to achieve a maximum of 10 repetitions. Resistance
Fig. 3 Foot and ankle exercises.(Left): Anti-pronation exercise: The rearfoot is supinated (with tactile feedback) whilst maintaining first metatarsal
head in ground contact. The white non-elastic tape is placed under the distal first metatarsal and the participant asked to prevent it from being
removed (i.e., through plantarflexion of the first ray) by the clinician who exerts traction on the tape. (Right) Calf stretch exercise, which is performed
with the foot in netural position and the midline of the foot and the mid-point of the patella kept perpendicular to the wall
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(denoted by band colour) and length (50, 60, 70 cm
loops) of the band (Theraband™) will be selected by the
physiotherapist to suit individual participant capacity,
re-evaluated at each treatment session and progressed
accordingly. Using an 11-point scale of perceived exer-
tion, participants will be encouraged to exercise at a rate
of 5–7 (‘Hard’ to ‘very hard’) (Table 2). The contraction
phase for each repetition will be 2 s concentric, 1 s iso-
metric, 2 s eccentric and 1 s rest; with approximately a
90 s rest between each set of 10 repetitions, while train-
ing the contralateral side.
For each of the twelve sessions, the treating physio-
therapist will record attendance, strength (colour) and
length of band used for each exercise, number of sets
Fig. 4 Hip abduction exercise in side lying
Fig. 5 Hip abduction exercise in standing
Matthews et al. Journal of Foot and Ankle Research  (2017) 10:5 Page 6 of 21
and repetitions completed as well as any adverse effects.
At the completion of the program, participants will be
instructed to continue with normal activities of daily living
with no instructions to continue on with a home exercise
program.
Outcome measures
The outcome measures will be a range of self-reported
questionnaires, including psychological and quality of
life measures as these are often involved in persistent
musculoskeletal pain conditions, and functional tasks
that load the patellofemoral joint. Participants will not
be made aware of the specific study aim to evaluate
midfoot width mobility as a treatment effect modifier so
as to minimise the impact of participant expectation of
treatment response on the basis of their foot type (or
their allocated treatment group). Baseline and follow up
(6 and 12 weeks after the commencement of interven-
tion) outcome measures will be administered by an
assessor at each trial site who will be blind to the partici-
pant’s midfoot width mobility measurement and inter-
vention allocation.
Primary outcome measurement (6 and 12 weeks)
The global rate of change scale (GROC) is the primary
outcome measure with the primary endpoint at 12 weeks.
Fig. 6 Hip extension exercise in standing
Fig. 7 Hip external rotation exercise in supine and with the hip in 30° flexion
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The GROC is a participant rating of the direction and
magnitude of overall change in symptoms [34]. Partici-
pants will be asked: “How would you describe your
knee pain now, compared to before you began the
treatment.” They will answer this question by selecting
a descriptor on a 7-point Likert scale that best represents
any change in their symptoms (much better, better, a little
better, no change, a little worse, worse, much worse).
Global rating of change scales have been frequently used
in studies investigating treatment outcome in those with
PFP and shown to be a flexible, simple and sensitive
method for measuring meaningful individual improve-
ment [10, 11, 35–37]. For analysis purposes, the GROC
will be dichotomized so that ‘much better’ and ‘better’ rep-
resent success with treatment.
Secondary outcome measures
Single assessment numeric evaluation (SANE): Single
assessment numeric evaluation questions have been used
previously in participants with neck pain [38], shoulder
surgery [39] and anterior cruciate ligament reconstruc-
tion [40] and been shown to correlate well with other
outcome measures. Participants will be asked:
(i) “How would you rate your knee today as a
percentage of normal on a scale of 0% to 100%?”
with 100% being defined as having no problems at
all with the knee. (at 0, 6 and 12 weeks)
(ii)“On a scale of 0 (not at all) to 100% (totally
recovered), how well do you feel you have recovered
from your knee pain?” (at 6 and 12 weeks)
Patient acceptable symptom state (6 and 12 weeks):
Patient acceptable symptom state is defined as the highest
level of symptom beyond which patients consider them-
selves well [41]. Patient acceptable symptom state has
been used in musculoskeletal and rheumatic conditions
and shown to provide information about a patient’s
improvement exceeding the minimally clinically important
improvement [41–43]. Participants will be asked to
answer yes or no to a structured question: “Is your current
condition satisfactory, when you take your general func-
tioning and your current pain into consideration?”
Perception of success and willingness to recommend
the treatment (6 and 12 weeks): Participants will be
asked to answer yes or no to two questions in regards to
their perception of the success of their treatment:
(i) “Overall, would you agree that the treatment you have
received has been successful for your knee pain?”
(ii)“If a good friend has the same knee pain as you,
would you recommend the same treatment you
received?”
Patient satisfaction (6 and 12 weeks): Participants will
be asked two questions in regards to the satisfaction of
their treatment with a selection of five possible responses
(very satisfied, somewhat satisfied, neither satisfied not
dissatisfied, somewhat dissatisfied, very dissatisfied). The
questions will be:
(i) “Over the course of treatment for your knee pain,
how satisfied were you with your overall treatment?”
(ii)“If you had to live with the symptoms you have
right now, how would you feel about it?”
Numerical pain rating scale (0, 6 and 12 weeks): The
numerical pain rating scale (NPS) can be a verbal or
visual scale to grade the intensity of pain experienced by
the participant and is recommended for research pur-
poses [44]. Participants will be asked to indicate a score
that best represents the intensity of their knee pain on
an 11-point scale where 0 represents no pain and 10
represents worst pain imaginable. Participants will pro-
vide two ratings; their average pain over the previous
seven days and their worst pain over the previous seven
days. An improvement of ≥ 2 on the NPS indicates
clinically meaningful change [45, 46].
Patient specific functional scale (0, 6 and 12 weeks):
Participants will self-select up to five tasks or activities
that are impaired due to their symptoms. Participants
will then rate the level of impairment of each task/activity
on an 11-point scale from 0 (“unable to perform activity”)
to 10 (“able to perform activity at same level as before the
injury or problem”). The patient specific functional scale
is a reliable and valid tool that is sensitive to changes in
patient’s symptoms [47, 48]. It has been reported that a
change of three or more on an individual patient-
nominated activity indicates a true change in functional
capacity [48].
Kujala Patellofemoral Scale (0, 6 and 12 weeks): This
questionnaire comprises 13 items designed specifically
Table 2 Borg scale of perceived exertion
1-10 Borg Scale of Perceived Exertion
0 Rest
1 Really Easy
2 Easy
3 Moderate
4 Sort of Hard
5 Hard
6
7 Really Hard
8
9 Really, Really Hard
10 Maximal
Matthews et al. Journal of Foot and Ankle Research  (2017) 10:5 Page 9 of 21
for PFP. Categories within the questionnaire cover a
range of knee functions under varying loads. Participants
select a response to each of the 13 items that best
depicts their symptoms. Each item is weighted separately
and then summed overall, with the highest possible
score of 100 points representing pain free full function
and 0 representing total incapacity. This questionnaire
has been recommended for knee pain because it is reliable
and sensitive to changes in symptoms [49–51]. A change
of 10 points is considered as the minimum clinically
important difference [50] in patients with PFP.
Knee injury and osteoarthritis outcome scale (KOOS)
(0, 6 and 12 weeks): This questionnaire is comprised of
five separate subscales that assess the patient’s opinion
of their knee and symptoms. The subscales cover pain,
symptoms, activities of daily living function, sporting
and recreation function and quality of life. Each subscale
consists of standardized answers (five Likert boxes), with
each question scored 0–4 separately. The questionnaire
will be scored according to the 2012 KOOS scoring
manual. Participants select a response to each question
in each subscale that best depicts their symptoms. Each
subscale will be normalised to a scale of 0–100 (0 = ex-
treme problems, 100 = no problems). A change of 8–10
points is suggested to represent a clinically significant
change in symptoms [52].
Hospital anxiety and depression scale (HADS) (0, 6
and 12 weeks): This 14-item scale will be used to investi-
gate emotional states of those with PFP. It has been
found to be a reliable instrument for detection of anxiety
and depression in an outpatient setting and a valid indi-
cator of severity [53, 54]. Participants are required to
select the best of four responses to questions pertaining
to either anxiety or depression (seven questions each),
which are scored from 0 to 3. The scores for the anxiety
and depression questions are summed separately to give
total scores for each component, where 0–7 represents
no anxiety or depression, 8–10 is borderline, and 11–21
indicates the presence of an anxious or depressive state.
Euro-Qol™ (EQ-5D 3 L version) (0, 6 and 12 weeks):
This validated questionnaire is used as a measure of
health outcome and provides a simple descriptive profile
and a single index value for health status. It compro-
mises of five domains about mobility, usual activities,
self care, pain and discomfort, and anxiety or depression
[55]. Participants will be asked to rate their impairment
on each domain (none, moderate or severe problems).
Each health state is scored (1–3) and transformed into
an index score. This score is used to derive quality-
adjusted life years as an outcome measure and is one of
the most commonly used economic evaluations used to
inform decisions in health care [56]. The participant
scores their overall health on a 0 to 100 scale, where 100
represents complete health and well-being [55].
Tampa scale for kinesophobia (TSK) (0, 6 and
12 weeks): The TSK is a 17-item questionnaire aimed at
assessing fear of reinjury due to physical movement [57].
Each item is scored on a 4-point Likert scale that ranges
from strongly disagree (1) to strongly agree (4). The
inverse scores from items 4, 8, 12, and 16 are used to cal-
culate the total score. Total TSK scores range between 17
and 68, with higher scores suggestive of higher levels of
fear of physical movement and vulnerability.
Pain Catastrophising Scale (PCS) (0, 6 and 12 weeks):
The PCS is a 13-item valid and reliable questionnaire
that evaluates a participant’s level of pain catastrophic
thinking, and classifying this into levels of rumination,
magnification and helplessness [58]. Participants are
asked to reflect on past painful experiences, and to indi-
cate the degree to which they experienced certain
thoughts or feelings when experiencing pain, on 5-point
scales from not at all (0) to all the time (4). The PCS yields
a total score and three subscale scores for rumination,
magnification and helplessness respectively. The total
score ranges from 0 – 52, with higher scores indicating
higher levels of pain catastrophization.
Functional tests: Step down, step up and squat (0, 6
and 12 weeks): These functional tests are commonly
reported as aggravating activities by patients with PFP
because they load the patellofemoral joint and have been
previously used in clinical trials [10]. Repeated step testing
will be performed on a single 25 cm step in time with a
metronome set at 96 beats per minute (e.g., stepping up/
down on each beat). Repeated squats will be performed in
time with a metronome set to 96 beats per minutes feet
shoulder width apart, squatting down in two beats, until
the participant can touch both lateral malleoli with their
fingers, and standing up over two beats. Activities will be
stopped when either a) onset of symptoms occurs, or b)
there is an increase in existing symptoms or c) when a
maximum of 25 repetitions has been reached without the
onset of pain.
Physical measurements
An examiner at each trial site, who is blinded to treat-
ment allocation and midfoot width mobility stratifica-
tion, will collect self-reported questionnaires (i.e., pain
scores, Kujala Patellofemoral Scale, etc.), physical mea-
surements and demographic data prior to commence-
ment of the intervention and at follow-up. Physical
measurements will include foot posture measurements,
ankle, hip and first metatarsophalangeal range of motion
measurements and maximal isometric hip strength test-
ing. These measures will be used in post-hoc analyses of
prognostication and identification of other possible can-
didates for treatment effect modifiers.
Midfoot width and height mobility: Measurement of
the width and height at the midfoot (i.e. 50% of total
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foot length) has been previously described and demon-
strated to be reliable [17]. In brief, these measurements
are performed on a foot measurement platform that can
standardize foot position by placing heels 15.24 cm apart
with the first metatarsal heads against a guide with body
weight equally distributed on both feet. Midfoot width
in weight bearing is measured using a digital caliper with
extend arms, which are positioned perpendicular to the
sole of foot and adjacent to lateral and medial aspect of
the foot at the 50% length (Fig. 8). This is repeated in
non-weight bearing with the patient seated on a height
adjustable table and legs hanging freely (Fig. 9). Midfoot
height (dorsal arch height) measurements at 50% of the
total foot length in weight bearing (bipedal stance) and
minimal weight bearing postures will also be taken
(Fig. 10) [17]. To measure the arch height in a minimal
weight bearing posture, the participant sits on a height
adjustable plinth with their feet hanging freely. The
assessment platform is positioned under both feet and
the plinth is lowered until the point of the heel being
assessed just contacts the platform. The vertical height
of the arch is then measured. The height and width mea-
surements of each foot in weight bearing and non (or
minimal) weight bearing will be recorded separately
three times and then averaged to give a single value for
the analysis. The change in midfoot height and width is
calculated by subtracting the measures in the two weight
bearing conditions.
Navicular drop: The participant stands barefoot with
equal weight on both feet. The navicular tuberosity will
be identified using palpation and the most prominent
point marked using a water-soluble ink pen. With the
patient standing in subtalar joint neutral position (de-
fined by palpation of the talus in the mortise and scored
‘0’ on the foot posture index [59]), the height of the
navicular tuberosity will be measured using a clear angle
ruler. The participant is instructed to relax their feet and
the navicular tuberosity height is re-measured. The dif-
ference in height measurements between a subtalar joint
neutral and relaxed foot position will be calculated to
determine the amount of navicular drop [60–63].
The Foot Posture Index (FPI-6): Relaxed foot posture
will be assessed using the FPI-6, which consists of six
criteria: (i) talar head palpation, (ii) curves above and
below the lateral malleoli, (iii) inversion/eversion of the
calcaneus, (iv) bulge in the region of the talonavicular
joint, (v) congruence of the medial longitudinal arch and
(vi) abduction/adduction of the forefoot on the rearfoot
[59]. Each criterion is examined and scored on a 5-point
scale between −2 and +2, which are then totaled to
categorize the foot as being highly pronated, pronated,
normal, supinated, or highly supinated [59]. Intrarater
reliability has been reported to be very good with inter-
rater reliability being only moderate between three
raters [64, 65].
Weight bearing bent knee ankle dorsiflexion (Lunge
Ankle Dorsiflexion Device - LAD): Bent knee ankle
dorsiflexion will be measured using a bespoke device,
the Lunge Ankle Dorsiflexion measurement device
(LAD). The LAD device has been previously described
[66]. In brief, the LAD was designed with only one
degree of freedom of motion in the sagittal plane. The
patient’s foot is aligned in a sagittal plane with a line that
bisects the 2nd and 3rd phalanges and the midline of
the posterior calcaneus. Whilst maintaining the toe in
light contact with the front of the reference block, the
participant slowly lunges forward, with the knee in con-
tact with a mobile measurement indicator. The therapist
focuses on ensuring that the three points remain in the
sagittal plane by watching for heel drift (usually medially)
Fig. 8 Midfoot width measured in weight bearing
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and heel lift, which indicates that full dorsiflexion has
been reached. The linear measurement of horizontal dis-
tance between anterior knee and the fixed reference block
at the longest toe is read from a ruler (mm).
Hip strength: Strength of the hip abductors, adductors
and external rotators will be measured at baseline, 6 and
12 weeks as dysfunction in these muscle groups has
been identified as a common impairment within the PFP
population, [67–69] and will be used in post hoc
exploratory prognostic analyses. Force produced during
a maximal voluntary isometric contraction (MVIC) will
be measured with a hand held dynamometer (Nicholas,
Lafayette, IN47903, USA) Measurements will take place
in supine to minimize the effect of gravity during testing
and compensatory contractions [70]. Each participant
will complete two practice contractions (50% MVIC
followed by 100% MVIC) followed by three experimental
MVICs where the participant will be asked to contract
maximally for 5 s. Participants will have a 30 s rest
between each contraction. The peak force (Newtons) will
be recorded for each contraction and converted to
torque (using the distance between the point or rotation
and placement of dynamometer as the lever arm) stan-
dardized to body mass (Nm/kg). Hip abductor and hip
adductor muscle strength will be tested using a dyna-
mometer 5 cm proximal to the lateral and medial malle-
olus respectively, and stabilised by a rigid belt. The test
leg will be extended in 0° abduction and 0° flexion, with
the non-test hip and knee flexed (Fig. 11). Hip external
rotation will be measured in supine with the hips in 30°
of flexion with the dynamometer 5 cm proximal to the
medial malleolus, stabilised in a solid bracket, fixated to
Fig. 9 Midfoot width measured in non-weight bearing
Fig. 10 Midfoot arch height measurement
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the testing device (Fig. 12). This testing position was
chosen because it: corresponds to biomechanical data on
muscular actions of the external rotators in various de-
grees of hip flexion (i.e., piriformis being an external rota-
tor muscle at 0° flexion and functionally switch rotation
action to internal rotation at >60° hip flexion); [71, 72]
replicates the position of exercise in the hip intervention
protocol [27]; and approximates the degrees of hip flexion
relative to the pelvis during foot contact/limb loading in
the initial stance phase of gait [73–75].
Limb length for the hip abductor and adductor mea-
surements, will be measured from the participant’s
anterior superior iliac spine to a mark 5 cm proximal
from the lateral and medial malleolus, respectively. For
hip external rotation, distance will be measured from the
medial joint line to a mark 5 cm proximal to the medial
malleoli. Participants will be instructed to hold the sides
of the plinth for stabilization and receive a standard ver-
bal encouragement with consistent level of volume and
enthusiasm.
Hip range of motion: Passive hip internal and external
rotation range of motion will be measured in upright sit-
ting, arms crossed, knees flexed to 90° over the edge of
the plinth and the non-test leg stabilised by a rigid belt.
The hip will be passively rotated to the point of resistance
with no compensatory pelvic motion. Range will be mea-
sured using a plurimeter placed 5 cm proximal to the tip
of the tibial malleoli on the medial border of the tibia for
external rotation, and 5 cm proximal to the tip of the
lateral malleoli to measure internal rotation (Fig. 13).
Demographic and other information: Other baseline
measurements to be collected will include age, sex, height,
weight, body mass index (BMI), unilateral and bilateral
symptoms, duration of symptoms, use of medications,
Fig. 11 Hip abduction strength testing
Fig. 12 Hip external rotation strength testing in 30° hip flexion
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physical activity levels, joint mobility using the Beighton
and Horan Joint Mobility Index [59, 64] and reported
crepitus during daily living activities.
Participant timeline
Volunteers will be recruited into the study through a
structured process involving a comprehensive advertising
campaign followed by verbal and physical examination
screening of eligibility by a registered physiotherapist. Par-
ticipants who meet the eligibility criteria will be offered
enrolment into the study, complete consent forms then
undergo baseline measurements and randomly allocated
to an intervention (Fig. 14). Participants with bilateral
symptoms will nominate their most symptomatic knee to
be used in analysis. The timeline for events (e.g., outcome
measure timepoints and close out) are shown in Table 3.
Sample size
Sample size was based on proportions of patients rating
themselves as “better” or “much better” on the Global
Rating of Change (GROC) score in the foot orthoses and
hip exercise treatment groups. The primary aim of the
study is to determine whether midfoot width mobility is
a treatment effect modifier for foot orthoses when com-
pared to progressive resisted hip exercises. This requires
testing for an interaction between midfoot width mobility,
dichotomised as high (≥11 mm) or low (<11 mm), and
treatment group. Based on previous findings, which indi-
cated a strong effect of foot orthoses in patients with PFP
who had a midfoot mobility ≥11 mm, [11] we wanted to
be able to detect an interaction effect of 50 percentage
points. This means that the difference between the foot
orthoses and hip exercise groups in the proportions of
participants who are improved at 12 weeks will be 50 per-
centage points higher (favoring foot orthoses) in partici-
pants with high midfoot width mobility than in those with
low midfoot width mobility. A sample of 30 participants
(15 per group) who have high midfoot width mobility pro-
vides 80% power using a two-sided significance level of
0.05 to detect a difference between the proportions of par-
ticipants with improvement of 30% in the hip exercises
group compared to 80% in the foot orthoses group.
Assuming that 20% of participants will be in the high mid-
foot width mobility group, we inflated the sample size to
188 participants (94 per group) to ensure adequate power
to detect this interaction effect of 50 percentage points
[76]. To allow loss to follow-up of up to 15%, the final
sample size was 220 participants (110 per group).
Recruitment
A comprehensive recruitment strategy, successfully uti-
lized in previous clinical trials [11, 18] will be used in
regions of Brisbane, Australia and Aalborg, Denmark.
The recruitment strategy involves paid advertisements in
local and regional newspapers, supplemented by adver-
tisements on university, gymnasium and community
websites, online social media, electronic and paper noti-
ceboards within the catchment area at regular intervals
during the recruitment period. Further referrals may
come from physiotherapists involved in the study and
general practitioners, through the provision of information
and advertising packages at their practices. Volunteers
who express interest in participating will be screened
through the previously described two-stage screening
process to determine eligibility.
Fig. 13 Hip internal and external range of motion measuring
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Allocation
Once informed consent and baseline measurements have
been obtained, each participant will be randomly allocated
to one of two intervention groups via concealed allocation
and assigned a participant code. An independent off-site
body will generate a randomization schedule for all par-
ticipants at both the Australian and Danish sites. The
randomization schedule will be generated by computer
and allocate on a 1:1 basis to each of the treatments with
stratification on the midfoot width mobility measure.
Data collection and management
All data will be collected in paper format and subse-
quently entered into an electronic study database. A num-
ber of strategies have been employed to ensure fidelity of
data entry, such as entries will be screened at random by a
second investigator to ensure entry is correct. The study
database has been developed in a regulatory approved
electronic medical records platform (OpenClinica®) by
the Clinical Trials and Biostatistics Unit. This database
will be used to comprehensively collect all safety and
efficacy related data, along with additional information for
possible exploratory analyses. The database development,
testing, validation and management strictly follow the
regulatory guidelines for clinical trial data management.
All participant data will be analysed on an intention-to-
treat basis. Once a participant is enrolled, every reasonable
effort will be made through paper and electronic media to
maintain contact and follow the participant for the dur-
ation of the trial period. It is anticipated that the rate of
Fig. 14 Flowchart of participants through trial (consort)
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loss-to-follow-up will be at most 10%. Participants will be
informed they may withdraw from the study at any time,
for any reason without any consequences. Participants
may be withdrawn from the study in order to protect their
safety (e.g., the foot orthoses intervention is unable to be
made comfortable to wear) after consulting with the
senior investigator (BV).
Statistical methods
A biostatistician who is blind to treatment group alloca-
tion and midfoot width mobility will conduct analysis.
All participants who have missing data and did not fully
comply with the treatment protocol will be included in
analyses. Demographic characteristics will be inspected to
assess baseline comparability of treatment groups and
compare those participants who remain in the study and
those who withdraw. If the proportion of missing data for
endpoints exceeds 5%, multiple imputation methodology
will be applied. To test the hypothesis of interaction
between randomised group and foot mobility, terms for
randomised group and foot mobility group, together with
an interaction between the two, will be included in
models. For the primary outcome (dichotomised GROC)
and other binary secondary outcomes, binary regression
Table 3 SPIRIT figure. Schedule of enrolment, interventions and assessments
Trial period
Enrolment Allocation Intervention period Follow up Close out
May 2014–
November 2016
May 2014–
November 2016
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 6 August 2014 –
Feb 2017
Enrolment
Eligibility screening X
Informed Consent X
Allocation X
Intervention
Foot orthoses X X X X X X
Hip exercises X X X X
Assessment
Diagnosis X
Midfoot width mobility X
Demographics X
Global rating of change X X
Rate of recovery X X
Patient acceptable
symptom state
X X
Numerical pain rating X X X
PSFS X X X
Kujala X X X
KOOS X X X
HADS X X X
Euro-QoL X X X
TSK X X X
PCS X X X
Functional tests: step up,
step down, squat
X X X
Navicular height X X
Midfoot height mobility X X
Isometric hip strength
testing
X X X
Range of motion measures X X X
Kujala Kujala patellofemoral pain scale, PSFS patient specific functional scale, KOOS knee injury and osteoarthritis outcome scale, HADS hospital anxiety and
depression scale, TSK Tampa scale for kinesophobia, PCS pain catastrophising scale
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models with a logarithmic link will be fit. For other out-
comes, linear regression models will be fitted, and as-
sumptions will be assessed using standard diagnostic
plots. To test for an overall treatment effect, regression
models for outcomes will include terms for randomised
group and foot mobility (as foot mobility is a stratifying
variable).
We will also undertake a secondary analysis to further
explore the relationship between midfoot width mobility
and the outcome, whereby midfoot width mobility will
be included in the model as a continuous variable,
together with an interaction term with randomised
group. Relationships will be investigated using fractional
polynomials [77]. We elected to perform this secondary
analysis because previous studies that identified midfoot
width mobility as a potential predictor of outcome after
foot orthoses used data-dependent techniques in relatively
small samples to establish a cut-off value for “high” mid-
foot width mobility. The concern with establishing cut-off
values with data-dependent techniques is that, while the
cut-off value may have been “optimal” for the original
sample, this same cut-off value may not be optimal in the
larger population [78, 79].
Monitoring
A safety committee will be established when the need
arises. It is not anticipated that a safety committee will
need to convene much or at all, because the treatments
have been previously studied with no reported serious ad-
verse events, are common to everyday practice for this
condition and there is low perceived risk to participants.
Participants and the treating physiotherapists are instructed
to report any adverse effects. Adverse effects reported by
participants or documented by the physiotherapists during
the treatment phases of the trial will be managed and re-
ported (to ethics and relevant institutional unit) as per ap-
propriate policies and procedures at the relevant site.
Adverse events
Participants will be instructed to report any adverse
events to the treating physiotherapists, and/or the
trial investigators. Adverse effects reported by partici-
pants or treating physiotherapists during the treat-
ment phases of the trial will be recorded, managed and
reported (to ethics and relevant institutional unit) as per
appropriate policies and procedures at the relevant site
immediately. Appropriate follow up health and medical
care will be recommended should it be required for any
adverse event. All cases of adverse events will be followed
up to ensure resolution.
Discussion
The primary aim of this trial is to determine whether
midfoot width mobility is a treatment effect modifier for
foot orthoses compared to hip exercises. The ability to
confidently predict a preferential response to any physical
treatment for PFP, such as foot orthoses, has proven elu-
sive to date and has at times been somewhat contentious
[19, 80, 81]. Follow up analyses of previous work in our
research unit [11, 18] on two different samples of partici-
pants with PFP has revealed that a reliable and easily
administered measure of midfoot width mobility might
predict those who will report a successful outcome after
receiving foot orthoses. For example, a randomized
clinical trial reported a success rate of 78% (7 of 9
cases) with foot orthoses in patients with PFP who had
high midfoot width mobility compared to only a 20%
success rate (2 of 10 cases) in those who had low midfoot
width mobility [11]. Methods for defining a successful out-
come and categorizing midfoot width mobility were simi-
lar to those being used in this current protocol. A
successful outcome was unlikely to be related to natural
history because only 5% (1/20) of the participants in the
wait-and-see group had a successful outcome. A signifi-
cant limitation of these data is that single group analyses
were used [19]. Absence of a comparison group in the
analysis means it is not possible to differentiate predictors
of the general course of the condition regardless of
treatment (i.e. prognostic factors) from predictors of
outcome to a specific treatment (i.e. treatment effect
modifiers) [16].
The design of the FOHX trial allows for robust testing
of midfoot width mobility as a treatment effect modifier
for foot orthoses compared to progressive resisted hip
exercises in individuals who have PFP. It will first test if
midfoot width mobility of ≥11 mm, which was defined
on the basis of our previous work [11] will predict a pref-
erential response to foot orthoses versus hip exercises.
Given that this previous work was based on small sample
sizes, we will also conduct a secondary analysis, in which
midfoot width mobility will be treated as a continuous
level measure to ensure that we have fully evaluated the
hypothesis that midfoot width mobility is a treatment
effect modifier. If the hypothesis is confirmed, then mid-
foot width mobility could help clinicians tailor treatment
for patients who have PFP.
Apart from our previous research suggesting that
midfoot width mobility may be predictive of a success
following treatment with foot orthoses, there is prima
facie evidence to support that foot orthoses will be more
successful when the patient has a mobile foot. Distal to
the knee, abnormal foot pronation has been hypothe-
sised to induce adverse lower limb kinematic motions,
which are associated with excessive load at the patellofe-
moral joint [82, 83]. Foot orthoses have a mechanical
effect on foot pronation [84], so it is plausible that foot
orthoses might have a mechanical effect on the patello-
femoral joint [85–87]. Interestingly, a modeling study of
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foot orthoses on patellofemoral joint load indicated that
while there was a significant effect, there was consider-
able inter-individual variation in the response [85] which
further underpins the need to determine whether mid-
foot width mobility is a treatment effect modifier for
foot orthoses. There is also a growing body of evidence
that supports the efficacy of foot orthoses for people
with PFP [10, 11, 88] but these clinical trials did not
specifically examine if the foot orthoses were most useful
in patients with mobile feet.
The head-to-head comparison between treatments
that target regions distal and proximal to the patellofe-
moral joint has not been done, making the clinical trial
outlined in this protocol novel. Proximal to the knee,
neuromuscular dysfunctions at the hip and pelvis have
been hypothesised to impact upon the patellofemoral
joint kinematics [83, 89, 90]. Evidence suggests weakness
of the postero-lateral hip musculature in primarily the
hip abductor and external rotator muscle groups as a
common impairment in those with PFP [67, 68, 91, 92].
Clinical trials that have compared isolated postero-
lateral hip musculature exercises to no exercises or as
part of a rehabilitative program have reported beneficial
outcomes for patients who have PFP [12, 27–31]. This
evidence supports exercises targeting the posterolateral
hip musculature as a viable treatment option for those
with PFP, and an appropriate comparator treatment
option in this trial.
This trial protocol aims to minimise potential biases,
optimise methodological quality and report pragmatic
clinical findings by addressing key methodological limi-
tations of previous studies that have aimed to investi-
gate treatment effect modifiers for PFP. Key strengths
of the trial include: (i) randomization of participants
according to a schedule that will be generated by an
independent body, (ii) enrollment based on pre-
determined criteria by registered physiotherapists and
independent of treatment allocation, (iii) participant
stratification into pre-determined subgroups based on
preliminary data, (iv) blinding of participants, assessors
and therapists to critical information (e.g., trial hypoth-
esis, stratification status, treatment allocation, baseline
and follow-up outcome measures), (v) head-to-head
comparison of two efficacious treatments for PFP, (vi)
sufficiently powered sample size to detect a significant
and substantial effect of midfoot width mobility as a
treatment effect modifier for foot orthoses, (vii) blinded
analysis using a pre-determined statistical analysis plan,
and (viii) conducting a pre-specified secondary analysis
to further evaluate midfoot width mobility as a treatment
effect modifier for foot orthoses when it is a continuous
variable. The findings from this trial will be reported in
accordance to the CONSORT statement [21] and widely
disseminated.
Conclusion
In conclusion, this trial sets out to address two conten-
tious issues that confront clinicians who treat patients
with PFP. One looks to assist the clinician in determin-
ing who is likely to have a preferential response to foot
orthoses treatment, compared to hip exercises, by testing
if a simple, clinically applicable measurement of midfoot
width mobility can be used to predict a better outcome.
The second is to assist in optimising the management
of PFP by comparing hip exercises to the use of foot
orthoses.
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